BIOTECH & PHARMA

    Biotech and pharma stocks listed on the ASX.

    Amplia Therapeutics ASX ATX cancer fibrosis AMP945 small molecule focal adhesion kinase FAK inhibitor program

    Amplia Therapeutics prepares for phase two AMP945 trial backed by shareholders

    Little Green Pharma ASX LGP transformational quarter acquisition distribution deals cannabis oil

    Little Green Pharma posts ‘transformational quarter’ of acquisition and distribution deals

    Incannex Healthcare ASX IHL CMAX Clinical Research South Australia managed Avance Clinical soft gel

    Incannex Healthcare begins clinical trial using IHL-675A soft gel capsules

    Invex Therapeutics ASX IXC 2021 quarter development Presendin idiopathic intracranial hypertension

    Invex Therapeutics closes busy quarter of development on Presendin for idiopathic intracranial hypertension

    PharmAust ASX PAA biotechnology patent application monepantel viral diseases aminoacetonitrile Patent Cooperative Treaty

    PharmAust lodges patent application for the use of monepantel in viral diseases

    Incannex Healthcare ASX IHL files patent application IHL-42X ethics approval open label extension obstructive sleep apnoea OSA

    Incannex files patent application for IHL-42X and receives ethics approval for open label extension

    Amplia Therapeutics ASX ATX Phase 1 clinical trial AMP945 cancer fibrosis

    Amplia Therapeutics phase 1 results support development of AMP945 in cancer and fibrosis

    Incannex Healthcare ASX IHL Unigel capsule technology formulations lead drug IHL-675A

    Incannex Healthcare appoints Procaps to develop capsule formulations for drug IHL-675A

    PharmAust ASX PAA Walter and Eliza Hall Institute antiviral MPL HTLV-1 monepantel human t-lymphotropic virus-1

    PharmAust collaborates with Walter and Eliza Hall Institute to test antiviral potential of MPL in HTLV-1

    PharmAust ASX PAA monepantel GMP tablet stability shelf-life

    Independent tests show PharmAust’s monepantel drug will retain long-term shelf-life and product stability

    Amplia Therapeutics ASX ATX Garvan Institute pancreatic cancer drug

    Amplia Therapeutics partners with Garvan Institute to develop pancreatic cancer drug

    PharmAust ASX PAA monepantel pet dogs B Cell Lymphoma interim clinical endpoints

    PharmAust’s monepantel trials to move to phase III after significant anti-cancer results

    Little Green Pharma ASX LGP Denmark Facility cannabis EU Europe

    Little Green Pharma accelerates medicinal cannabis growth plans with purchase of Danish manufacturing facility

    Incannex Healthcare ASX IHL Vectura traumatic brain injury tbi product registration

    Incannex Healthcare to develop IHL-216A formulation for traumatic brain injury clinical trials

    Little Green Pharma ASX LGP Medezin Pelion medicinal cannabis oil THC flower products Poland

    Little Green Pharma secures deal to distribute medicinal cannabis products in Poland

    Invex Therapeutics ASX IXC US Food and Drug Administration FDA Division of Neurology Type C Meeting clinical trial Presendin Exenatide treatment Idiopathic Intracranial Hypertension

    Invex Therapeutics receives US FDA feedback on planned Presendin trial targeting idiopathic intracranial hypertension

    Argenica Therapeutics ASX AGN stroke

    Argenica Therapeutics prepares for clinical trials of novel stroke treatment

    Creso Pharma Halucenex phase II psilocybin trial non-veteran PTSD sufferers ASX CPH

    Creso Pharma’s Halucenex expands phase II psilocybin trial to include non-veteran PTSD sufferers

    Little Green Pharma ASX LGP medicinal cannabis market share

    Growing market share is priority work for local medicinal cannabis producer Little Green Pharma

    Creso Pharma ASX CPH distribution agreement Route 2 Pharm Latin American cannabis market Ecuador

    Creso Pharma expands distribution agreement with Route 2 Pharm, eyes Latin American cannabis market

    Creso Pharma Halucenex Life Sciences Senate Bill 519 Californian State Senate decriminalise psychedelic drugs United States ASX CPH

    Creso Pharma and Halucenex expedite US market entry following proposed law to decriminalise psychedelic drugs

    Load more
    Small Caps ASX Australian stock market
    Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

    Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
    Copyright 2021 Small Caps. All rights reserved.